RxDoctor Payments Data

Nkechi Saleh, APRN

Psychiatric/Mental Health · Tucker, GANPI 1053869750

Payments from drug & device makers

$384in general payments, 2019–2025

Across 21 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$71
  • Otsuka America Pharmaceutical, Inc.$65
  • E.r. Squibb & Sons, L.L.C.$63
  • Johnson & Johnson$42
  • Idorsia Pharmaceuticals US Inc$40
  • Supernus Pharmaceuticals, Inc.$32
  • plus $71 from 3 others

What the payments were for

  • Food & beverage$33988%
  • Education$4512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$384 in reported general payments places this provider in the 50th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$24,672
Medicare patients
43
Services billed
310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate23$72,585
Abilify MaintenaAripiprazole15$47,458
SavellaMilnacipran Hcl60$29,857
CaplytaLumateperone Tosylate18$26,328
LybalviOlanzapine/Samidorphan Malate12$19,850
RexultiBrexpiprazole13$18,288
AuvelityDextromethorphan Hbr/Bupropion19$17,927
LatudaLurasidone Hcl12$17,050
Lurasidone Hcl41$13,027
Ziprasidone Hcl72$7,440
Aripiprazole50$5,809
Olanzapine69$4,938
Quetiapine Fumarate191$3,677
Desvenlafaxine Succinate ErDesvenlafaxine Succinate56$3,074
Lisdexamfetamine Dimesylate14$2,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$42$72,58523 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$65$65,74628 claims
Alkermes, Inc.Lybalvi$32$19,85012 claims
Axsome Therapeutics, Inc.Auvelity$28$17,92719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Tucker

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →